Letrozol Beta

Letrozole, the active ingredient in Letrozol Beta, is a aromatase inhibitor presented as an oral tablet for oral use. It is indicated for the treatment of postmenopausal hormone receptor‑positive breast cancer and for adjuvant therapy in early‑stage disease. GNH USA supplies Letrozol Beta as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

Letrozol Beta is an aromatase inhibitor used in the management of hormone‑dependent breast cancer. - Postmenopausal hormone receptor‑positive breast cancer: reduces tumour growth by lowering estrogen levels. - Adjuvant treatment of early‑stage breast cancer: lowers risk of disease recurrence after surgery. - Metastatic hormone receptor‑positive breast cancer: helps control disease progression in advanced cases.

Adverse reactions may occur with Letrozol Beta and are categorized by frequency.

Common Side Effects: - Hot flashes - Joint and muscle pain - Fatigue - Nausea - Headache - Dizziness

Serious or Rare Side Effects: - Severe liver injury - Bone fracture or osteoporosis - Pulmonary embolism - Anaphylactic or severe allergic reaction - QT interval prolongation - Significant cholesterol elevation

Before initiating Letrozol Beta, clinicians should consider several safety measures. - Bone health monitoring: assess baseline bone mineral density and consider calcium/vitamin D supplementation. - Liver function assessment: evaluate hepatic enzymes prior to therapy. - Cardiovascular risk evaluation: review history of thromboembolic events. - Avoid use in premenopausal women unless ovarian suppression is confirmed. - Use with caution in patients with hepatic impairment. - Store at room temperature: keep in the original container, protect from moisture and light.

Letrozol Beta may interact with other medicines, requiring attention to the interaction strength.

Major Interactions (Avoid): - Concomitant estrogen therapy: may counteract aromatase inhibition. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): reduce letrozole exposure. - Tamoxifen: antagonistic effect on estrogen pathways.

Moderate Interactions (Monitor Closely): - CYP2C19 inhibitors (e.g., fluconazole): may increase plasma levels. - Warfarin: potential alteration of anticoagulant effect. - Selective serotonin reuptake inhibitors (SSRIs): monitor for additive fatigue or dizziness.